Understanding Fibromyalgia: Lessons from the Broader Pain Research Community

Journal of Pain

Volumn 10, Issue 8, 2009, Pages 777-791

  Williams, David A ^a   Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

central sensitization; Fibromyalgia; nonpharmacological; sensory augmentation; stress; treatment

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMITRIPTYLINE; CITALOPRAM; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PRAMIPEXOLE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLPIDEM; ZOPICLONE;

BEDTIME DOSAGE; CHRONIC PAIN; COGNITION; COGNITIVE THERAPY; DIZZINESS; EDEMA; ENVIRONMENTAL STRESS; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART PALPITATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NAUSEA; NEUROBIOLOGY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL ASPECT; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WEIGHT GAIN;

BRAIN; FIBROMYALGIA; HUMANS; MODELS, NEUROLOGICAL; PAIN;

EID: 67650879535     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2009.06.001     Document Type: Review

References (177)

1. Aaron L.A., Bradley L.A., Alarcon G.S., Alexander R.W., Triana-Alexander M., Martin M.Y., and Alberts K.R. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 39 (1996) 436-445
2. Adelman L.C., Adelman J.U., Von Seggern R., and Mannix L.K. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache 40 (2000) 572-580
3. Adiguzel O., Kaptanoglu E., Turgut B., and Nacitarhan V. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: A prospective study with semiquantitative SPECT. South Med J 97 (2004) 651-655
4. Adler G.K., Kinsley B.T., Hurwitz S., Mossey C.J., and Goldenberg D. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 106 (1999) 534-543
5. Alfisi S., Sigal M., and Landau M. Primary fibromyalgia syndrome-A variant of depressive disorder?. Psychother Psychosom 51 (1989) 156-161
6. Anderberg U.M., Marteinsdottir I., and Von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study. Eur J Pain 4 (2000) 27-35
7. Apkarian A.V., Bushnell M.C., Treede R.D., and Zubieta J.K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9 (2005) 463-484
8. Arnold L.M., Keck Jr. P.E., and Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41 (2000) 104-113
9. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., and Goldstein D.J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
10. Arnold L.M., Hudson J.I., Hess E.V., Ware A.E., Fritz D.A., Auchenbach M.B., Starck L.O., and Keck Jr. P.E. Family study of fibromyalgia. Arthritis Rheum 50 (2004) 944-952
11. Arnold L.M., Russell L.J., Diri E.W., Duan W.R., Young Jr. J.P., Sharma U., Martin S.A., Barrett J.A., and Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9 (2008) 792-805
12. Arnold L.M., Goldenberg D., Stanford S.B., Lalonde J.K., Sandhu H.S., Keck Jr. P.E., Welge J.A., Bishop F., Stanford K.E., Hess E.V., and Hudson J.I. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56 (2007) 1336-1344
13. Arroyo J.F., and Cohen M. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 20 (1993) 1925-1931
14. Bair M.J., Robinson R., Katon W., and Kroenke K. Depression and pain comorbidity: A literature review. Arch Intern Med 163 (2003) 2433-2445
15. Baraniuk J.N., Whalen G., Cunningham J., and Clauw D.J. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 5 (2004) 48
16. Barsky A.J., and Borus J.F. Functional somatic syndromes. Ann Intern 130 (1999) 910-921
17. Benjamin S., Morris S., McBeth J., Macfarlane G.J., and Silman A.J. The association between chronic widespread pain and mental disorder: A population-based study. Arthritis Rheum 43 (2000) 561-567
18. Bennett R.M. Pharmacological treatment of fibromyalgia. J Funct Syndromes 1 (2001) 79-92
19. Bennett R.M., Kamin M., Karim R., and Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med 114 (2003) 537-545
20. Bennett R.M., Clark S.R., Goldberg L., Nelson D., Bonafede R.P., Porter J., and Specht D. Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 32 (1989) 454-460
21. Blumenthal J.A., Emery C.F., Madden D.J., Schniebolk S., Walsh-Riddle M., George L.K., Mckee D.C., Higginbotham M.B., Cobb F.R., and Coleman R.E. Long-term effects of exercise on psychological functioning in older men and women. J Gerontol 46 (1991) 352-361
22. Bondy B., Spaeth M., Offenbaecher M., Glatzeder K., Stratz T., Schwarz M., De Jonge S., Kruger M., Engel R., Farber L., Pongratz D., and Ackenheil M. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 6 (1999) 433-439
23. Bradley L.A., Alberts K.R., Alarcon G.S., Alexander M.T., Mountz J.M., Wiegent D.A., Liu H.G., Blalock J.E., Aaron L.A., Alexander R.W., San Pedro E.C., Martin M.Y., and Morell A.C. Abnormal brain regional cerebral blood flow and cerebrospinal fluid levels of Substance P in patients and non-patients with fibromyalgia. Arthritis Rheum 39 9S (1996) 1109
24. Burckhardt C.S., and Bjelle A. Perceived control: A comparison of women with fibromyalgia, rheumatoid arthritis, and systemic lupus erythematosus using a Swedish version of the Rheumatology Attitudes Index. Scand J Rheumatol 25 (1996) 300-306
25. Burton A.K., Tillotson K.M., Main C.J., and Hollis S. Psychosocial predictors of outcome in acute and subchronic low back trouble. Spine 20 (1995) 722-728
26. Busch A.J., Thille P., Barber K.A., Schachter C., Bidonde J., and Collacott B.K. Best practice: E-Model-prescribing physical activity and exercise for individuals with fibromyalgia. Physiother Theory Pract 24 (2008) 151-166
27. Buskila D., Sarzi-Puttini P., and Ablin J.N. The genetics of fibromyalgia syndrome. Pharmacogenomics 8 (2007) 67-74
28. Buskila D., Neumann L., Hazanov I., and Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 26 (1996) 605-611
29. Buskila D., Cohen H., Neumann L., and Ebstein R.P. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9 (2004) 730-731
30. Buskila D., Neumann L., Vaisberg G., Alkalay D., and Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 40 (1997) 446-452
31. Capaci K., and Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. The Pain Clinic 14 (2002) 223-228
32. Carville S.F., Arendt-Nielsen S., Bliddal H., Blotman F., Branco J.C., Buskila D., Da Silva J.A., Danneskiold-Samsoe B., Dincer F., Henriksson C., Henriksson K.G., Kosek E., Longley K., McCarthy G.M., Perrot S., Puszczewicz M., Sarzi-Puttini P., Silman A., Spath M., and Choy E.H. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67 (2008) 536-541
33. Clark S.R. Prescribing exercise for fibromyalgia patients. Arthritis Care Res 7 (1994) 221-225
34. Clauw D.J. The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses 44 (1995) 369-378
35. Clauw D.J. Commentary on the EULAR recommendations for the management of fibromyalgia. Nat Clin Pract Rheumatol 4 (2008) 392-393
36. Clauw D.J., and Chrousos G.P. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4 (1997) 134-153
37. Cohen H., Neumann L., Shore M., Amir M., Cassuto Y., and Buskila D. Autonomic dysfunction in patients with fibromyalgia: Application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 29 (2000) 217-227
38. Cohen M.L., and Quintner J. Fibromyalgia syndrome, a problem of tautology. Lancet 342 (1993) 906-909
39. Cook D.B., Lange G., Ciccone D.S., Liu W.C., Steffener J., and Natelson B.H. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 31 (2004) 364-378
40. Craig A.D. Distribution of trigeminothalamic and spinothalamic lamina I terminations in the cat. Somatosens Mot Res 20 (2003) 209-222
41. Craig A.D. Human feelings: Why are some more aware than others?. Trends Cogn Sci 8 (2004) 239-241
42. Crofford L.J., Pillemer S.R., Kalogeras K.T., Cash J.M., Michelson D., Kling M.A., Sternberg E.M., Gold P.W., Chrousos G.P., and Wilder R.L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37 (1994) 1583-1592
43. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., Young Jr. J.P., Lamoreaux L.K., Martin S.A., and Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
44. Demitrack M.A., and Crofford L.J. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci 840 (1998) 684-697
45. Diatchenko L., Nackley A.G., Tchivileva I.E., Shabalina S.A., and Maixner W. Genetic architecture of human pain perception. Trends Genet 23 (2007) 605-613
46. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., Goldman D., Xu K., Shabalina S.A., Shagin D., Max M.B., Makarov S.S., and Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14 (2005) 135-143
47. Drossman D.A., Li Z.M., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., Whitehead W.E., Janssens J., Funch-Jensen P., and Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38 (1993) 1569-1580
48. Dworkin R.H., Turk D.C., Wyrwich K.W., Beaton D., Cleeland C.S., Farrar J.T., Haythornthwaite J.A., Jensen M.P., Kerns R.D., Ader D.N., Brandenburg N., Burke L.B., Cella D., Chandler J., Cowan P., Dimitrova R., Dionne R., Hertz S., Jadad A.R., Katz N.P., Kehlet H., Kramer L.D., Manning D.C., McCormick C., McDermott M.P., McQuay H.J., Patel S., Porter L., Quessy S., Rappaport B.A., Rauschkolb C., Revicki D.A., Rothman M., Schmader K.E., Stacey B.R., Stauffer J.W., von Stein T., White R.E., Witter J., and Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9 (2008) 105-121
49. Figueroa A., Kingsley J.D., Mcmillan V., and Panton L.B. Resistance exercise training improves heart rate variability in women with fibromyalgia. Clin Physiol Funct Imaging 28 (2008) 49-54
50. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 32 (2000) 305-316
51. Fukuda K., Nisenbaum R., Stewart G., Thompson W.W., Robin L., Washko R.M., Noah D.L., Barrett D.H., Randall B., Herwaldt B., Mawle A.C., and Reeves W.C. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 280 (1998) 981-988
52. Geisser M.E., and Roth R.S. Knowledge of and agreement with chronic pain diagnosis: Relation to affective distress, pain beliefs and coping, pain intensity, and disability. J Occup Rehabil 8 (1998) 73-88
53. Geisser M.E., Robinson M.E., Keefe F.J., and Weiner M.L. Catastrophizing, depression and the sensory, affective and evaluative aspects of chronic pain. Pain 59 (1994) 79-83
54. Geisser M.E., Casey K.L., Brucksch C.B., Ribbens C.M., Appleton B.B., and Crofford L.J. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: Association with mood, somatic focus, and catastrophizing. Pain 102 (2003) 243-250
55. Geisser M.E., Glass J.M., Rajcevska L.D., Clauw D.J., Williams D.A., Kileny P.R., and Gracely R.H. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain 9 (2008) 417-422
56. Gendreau R.M., Thorn M.D., Gendreau J.F., Kranzler J.D., Ribeiro S., Gracely R.H., Williams D.A., Mease P.J., Mclean S.A., and Clauw D.J. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
57. Gerster J.C., and Hadj-Djilani A. Hearing and vestibular abnormalities in primary fibrositis syndrome. J Rheumatol 11 (1984) 678-680
58. Gibson S.J., Littlejohn G.O., Gorman M.M., Helme R.D., and Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58 (1994) 185-193
59. Giesecke J., Reed B.D., Haefner H.K., Giesecke T., Clauw D.J., and Gracely R.H. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet Gynecol 104 (2004) 126-133
60. Giesecke T., Gracely R.H., Williams D.A., Geisser M., Petzke F., and Clauw D.J. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 52 (2005) 1577-1584
61. Giesecke T., Gracely R.H., Grant M.A., Nachemson A., Petzke F., Williams D.A., and Clauw D.J. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 50 (2004) 613-623
62. Giesecke T., Williams D.A., Harris R.E., Cupps T.R., Tian X., Tian T.X., Gracely R.H., and Clauw D.J. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48 (2003) 2916-2922
63. Glass J.M., Lyden A., Petzke F., and Clauw D. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 57 (2004) 391-398
64. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA 292 (2004) 2388-2395
65. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
66. Gracely R.H., Geisser M.E., Giesecke T., Grant M.A., Petzke F., Williams D.A., and Clauw D.J. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 127 (2004) 835-843
67. Granges G., and Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 36 (1993) 642-646
68. Guedj E., Cammilleri S., Colavolpe C., De Laforte C., Niboyet J., and Mundler O. Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT. Eur J Nucl Med Mol Imaging 34 (2007) 2115-2119
69. Guedj E., Cammilleri S., Colavolpe C., Taieb D., De Laforte C., Niboyet J., and Mundler O. Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 34 (2007) 1274-1279
70. Guedj E., Taieb D., Cammilleri S., Lussato D., De Laforte C., Niboyet J., and Mundler O. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 34 (2007) 130-134
71. Guedj E., Cammilleri S., Niboyet J., Dupont P., Vidal E., Dropinski J.P., and Mundler O. Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med 49 (2008) 1798-1803
72. Gustafsson M., and Gaston-Johansson F. Pain intensity and health locus of control: A comparison of patients with fibromyalgia syndrome and rheumatoid arthritis. Patient Educ Couns 29 (1996) 179-188
73. Hamilton N.A., Affleck G., Tennen H., Karlson C., Luxton D., Preacher K.J., and Templin J.L. Fibromyalgia: The role of sleep in affect and in negative event reactivity and recovery. Health Psychol 27 (2008) 490-497
74. Hammett V.B. Psychological changes with physical fitness training. Can Med Assoc J 96 (1967) 764-769
75. Harris R.E., and Clauw D.J. How do we know that the pain in fibromyalgia is "real"?. Curr Pain Headache Rep 10 (2006) 403-407
76. Harris R.E., Clauw D.J., Scott D.J., Mclean S.A., Gracely R.H., and Zubieta J.K. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27 (2007) 10000-10006
77. Hoffman B.M., Papas R.K., Chatkoff D.K., and Kerns R.D. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol 26 (2007) 1-9
78. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
79. Hudson J.I., Hudson M.S., Pliner L.F., Goldenberg D.L., and Pope Jr. H.G. Fibromyalgia and major affective disorder: A controlled phenomenology and family history study. Am J Psychiatry 142 (1985) 441-446
80. Hudson J.I., Goldenberg D.L., Pope Jr. H.G., Keck Jr. P.E., and Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. A J Med 92 (1993) 363-367
81. Janal M.N. Pain sensitivity, exercise and stoicism. J R Soc Med 89 (1996) 376-381
82. Jensen M.P., Turner J.A., and Romano J.M. Changes after multidisciplinary pain treatment in patient pain beliefs and coping are associated with concurrent changes in patient functioning. Pain 131 (2007) 38-47
83. Jones S.L. Descending noradrenergic influences on pain. Prog Brain Res 88 (1991) 381-394
84. Julien N., Goffaux P., Arsenault L., and Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114 (2005) 295-302
85. Kato K., Sullivan P.F., Evengard B., and Pedersen N.L. Chronic widespread pain and its comorbidities: A population-based study. Arch Intern Med 166 (2006) 1649-1654
86. Kato K., Sullivan P.F., Evengard B., and Pedersen N.L. Importance of genetic influences on chronic widespread pain. Arthritis Rheum 54 (2006) 1682-1686
87. Kato K., Sullivan P.F., Evengard B., and Pedersen N.L. A population-based twin study of functional somatic syndromes. Psychol Med 39 (2009) 497-505
88. Keefe F.J., Brown G.K., Wallston K.A., and Caldwell D.S. Coping with rheumatoid arthritis pain: Catastrophizing as a maladaptive strategy. Pain 37 (1989) 51-56
89. Khan A.A., Khan A., Harezlak J., Tu W., and Kroenke K. Somatic symptoms in primary care: Etiology and outcome. Psychosomatics 44 (2003) 471-478
90. Kosek E., and Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 70 (1997) 41-51
91. Kosek E., Ekholm J., and Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 68 (1996) 375-383
92. Kuraishi Y., Hirota N., Satoh M., and Takagi H. Antinociceptive effects of intrathecal opioids, noradrenaline and serotonin in rats: Mechanical and thermal algesic tests. Brain Res 326 (1985) 168-171
93. Kwiatek R., Barnden L., Tedman R., Jarrett R., Chew J., Rowe C., and Pile K. Regional cerebral blood flow in fibromyalgia: Single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 43 (2000) 2823-2833
94. Lautenbacher S., and Rollman G.B. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 13 (1997) 189-196
95. Le Bars D, Villanueva L, Bouhassira D, Willer JC: Diffuse noxious inhibitory controls (DNIC) in animals and in man Patol Fiziol Eksp ter 55-65,1992
96. Leffler A.S., Hansson P., and Kosek E. Somatosensory perception in a remote pain-free area and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from long-term trapezius myalgia. Eur J Pain 6 (2002) 149-159
97. Maixner W., Fillingim R., Booker D., and Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 63 (1995) 341-351
98. Martinez-Lavin M., Hermosillo A.G., Rosas M., and Soto M.E. Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart rate variability analysis. Arthrit Rheumat 41 (1998) 1966-1971
99. Mayer E.A., and Raybould H.E. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99 (1990) 1688-1704
100. McBeth J., and Jones K. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 21 (2007) 403-425
101. McBeth J., Silman A.J., Gupta A., Chiu Y.H., Ray D., Morriss R., Dickens C., King Y., and Macfarlane G.J. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: Findings of a population-based prospective cohort study. Arthritis Rheum 56 (2007) 360-371
102. McCann I.L., and Holmes D.S. Influence of aerobic exercise on depression. J Pers Soc Psychol 46 (1984) 1142-1147
103. Mccarberg B., Wolf J., Oliver K., Fakhry F., Walen H., and Cronan T. The relationship between health locus of control and well-being in fibromyalgia patients. J Pain 3 2 (2002) 14
104. Mcdermid A.J., Rollman G.B., and Mccain G.A. Generalized hypervigilance in fibromyalgia: Evidence of perceptual amplification. Pain 66 (1996) 133-144
105. McGavin C.R., Gupta S.P., Lloyd E.L., and Mchardy G.J. Physical rehabilitation for the chronic bronchitic: Results of a controlled trial of exercises in the home. Thorax 32 (1977) 307-311
106. McLean S.A., Williams D.A., Harris R.E., Kop W.J., Groner K.H., Ambrose K., Lyden A.K., Gracely R.H., Crofford L.J., Geisser M.E., Sen A., Biswas P., and Clauw D.J. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 52 (2005) 3660-3669
107. McLean S.A., Williams D.A., Stein P.K., Harris R.E., Lyden A.K., Whalen G., Park K.M., Liberzon I., Sen A., Gracely R.H., Baraniuk J.N., and Clauw D.J. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 31 (2006) 2776-2782
108. Mease P., Arnold L.M., Bennett R., Boonen A., Buskila D., Carville S., Chappell A., Choy E., Clauw D., Dadabhoy D., Gendreau M., Goldenberg D., Littlejohn G., Martin S., Perera P., Russell I.J., Simon L., Spaeth M., Williams D., and Crofford L. Fibromyalgia syndrome. J Rheumatol 34 (2007) 1415-1425
109. Mease P.J., Russell I.J., Arnold L.M., Florian H., Young Jr. J.P., Martin S.A., and Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514
110. Mease P.J., Arnold L.M., Crofford L.J., Williams D.A., Russell I.J., Humphrey L., Abetz L., and Martin S.A. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient Delphi exercises. Arthritis Rheum 59 (2008) 952-960
111. Meldrum M. A capsule history of pain management. JAMA 290 (2003) 2470-2475
112. Minor M.A., Hewett J.E., Webel R.R., Anderson S.K., and Kay D.R. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 32 (1989) 1396-1405
113. Moldofsky H., Scarisbrick P., England R., and Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37 (1975) 341-351
114. Morley S., Eccleston C., and Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 80 (1999) 1-13
115. Moshiree B., Price D.D., Robinson M.E., Gaible R., and Verne G.N. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain 23 (2007) 323-330
116. Mountz J.M., Bradley L.A., Modell J.G., Alexander R.W., Triana-Alexander M., Aaron L.A., Stewart K.E., Alarcon G.S., and Mountz J.D. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 38 (1995) 926-938
117. Naliboff B.D., Derbyshire S.W., Munakata J., Berman S., Mandelkern M., Chang L., and Mayer E.A. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 63 (2001) 365-375
118. Norregaard J., Volkmann H., and Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61 (1995) 445-449
119. O'malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., and Jackson J.L. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med 15 (2000) 659-666
120. Offenbaecher M., Bondy B., De Jonge S., Glatzeder K., Kruger M., Schoeps P., and Ackenheil M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42 (1999) 2482-2488
121. Pastor M.A., Salas E., Lopez S., Rodriguez J., Sanchez S., and Pascual E. Patients' beliefs about their lack of pain control in primary fibromyalgia syndrome. B J Rheumatol 32 (1993) 484-489
122. Petzke F., Gracely R.H., Park K.M., Ambrose K., and Clauw D.J. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol 30 (2003) 567-574
123. Petzke F., Clauw D.J., Ambrose K., Khine A., and Gracely R.H. Increased pain sensitivity in fibromyalgia: Effects of stimulus type and mode of presentation. Pain 105 (2003) 403-413
124. Petzke F., Harris R.E., Williams D.A., Clauw D.J., and Gracely R.H. Differences in unpleasantness induced by experimental pressure between patients with fibromyalgia and healthy controls. Eur J Pain 9 (2005) 325-335
125. Petzke F., Khine A., Williams D., Groner K., Clauw D.J., and Gracely R.H. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 28 (2001) 2568-2569
126. Price D.D., Staud R., Robinson M.E., Mauderli A.P., Cannon R., and Vierck C.J. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99 (2002) 49-59
127. Qiao Z.G., Vaeroy H., and Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 18 (1991) 1383-1389
128. Raphael K.G., Natelson B.H., Janal M.N., and Nayak S. A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain 100 (2002) 131-139
129. Ren K., and Dubner R. NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw. Neurosci Lett 163 (1993) 22-26
130. Rossy L.A., Buckelew S.P., Dorr N., Hagglund K.J., Thayer J.F., Mcintosh M.J., Hewett J.E., and Johnson J.C. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 21 (1999) 180-191
131. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
132. Russell I.J., Michaelek J.E., Ziao Y., Haynes W., Vertiz R., and Lawrence R.A. Therapy with a central alpha 2-adrenergic agonist (tizanidine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis Rheum 46 9 (2002) S614
133. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., Lopez Y., and Mackillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37 (1994) 1593-1601
134. Sapolsky R.M. Why stress is bad for your brain. Science 273 (1996) 749-750
135. Sarchielli P., Di Filippo M., Nardi K., and Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 11 (2007) 343-351
136. Scharf M.B., Baumann M., and Berkowitz D.V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30 (2003) 1070-1074
137. Sjostrom S., Tamsen A., Hartvig P., Folkesson R., and Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg 67 (1988) 976-981
138. Smythe H.A., and Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bulletin on the Rheumatic Diseases 28 (1977) 928-931
139. Sonstroem R.J. Exercise and self-esteem. Exerc Sport Sci Rev 21 (1984) 329-337
140. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., and Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91 (2001) 165-175
141. Staud R., Carl K.E., Vierck C.J., Price D.D., Robinson M.E., Cannon R.L., and Mauderli A.P. Repetitive muscle stimuli result in enhanced wind-up of fibromyalgia patients. Arthritis Rheum 44 (2001) S395-S395
142. Stein P.K., Domitrovich P.P., Ambrose K., Lyden A., Fine M., Gracely R.H., and Clauw D.J. Sex effects on heart rate variability in fibromyalgia and Gulf War illness. Arthritis Rheum 51 (2004) 700-708
143. Stroud M.W., Thorn B.E., Jensen M.P., and Boothby J.I. The relation between pain beliefs, negative thoughts, and psychosocial functioning in chronic pain patients. Pain 84 (2000) 347-352
144. Sullivan M.J., Stanish W., Waite H., Sullivan M., and Tripp D.A. Catastrophizing, pain, and disability in patients with soft-tissue injuries. Pain 77 (1998) 253-260
145. Tracey I. Imaging pain. Br J Anaesth 101 (2008) 32-39
146. Tracey I., and Mantyh P.W. The cerebral signature for pain perception and its modulation. Neuron 55 (2007) 377-391
147. Tugwell P., Boers M., Brooks P., Simon L., Strand V., and Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 8 38 (2007)
148. Turk D.C. The Potential of Treatment Matching for Subgroups of Patients With Chronic Pain: Lumping Versus Splitting. Clin J Pain 21 (2005) 44-55
149. Turk D.C., Dworkin R.H., Revicki D., Harding G., Burke L.B., Cella D., Cleeland C.S., Cowan P., Farrar J.T., Hertz S., Max M.B., and Rappaport B.A. Identifying important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain. Pain 137 (2008) 276-285
150. Turner J.A., Jensen M.P., and Romano J.M. Do beliefs, coping, and catastrophizing independently predict functioning in patients with chronic pain?. Pain 85 (2000) 115-125
151. Vaeroy H., Helle R., Forre O., Kass E., and Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 32 (1988) 21-26
152. Vitton O., Gendreau M., Gendreau J., Kranzler J., and Rao S.G. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19 Suppl 1 (2004) 27-35
153. Welin M., Bragee B., Nyberg F., and Kristiansson M. Elevated Substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. Journal of Musculoskeletal Pain 3 (1995) 4
154. Wessely S., Chalder T., Hirsch S., Wallace P., and Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: A prospective study in the primary care setting. Am J Psychiatry 153 (1996) 1050-1059
155. White K.P., Nielson W.R., Harth M., Ostbye T., and Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 47 (2002) 260-265
156. Wiffen P., Collins S., McQuay H., Carroll D., Jadad A., and Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 3 (2000) CD001133
157. Wigers S.H., Stiles T.C., and Vogel P.A. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol 25 (1996) 77-86
158. Williams D.A. Psychological and behavioral therapies in fibromyagia and related syndromes. Baillieres Best Pract Res Clin Rheumatol 17 (2003) 649-665
159. Williams D.A., and Keefe F.J. Pain beliefs and the use of cognitive-behavioral coping strategies. Pain 46 (1991) 185-190
160. Williams D.A., Robinson M.E., and Geisser M.E. Pain beliefs: Assessment and utility. Pain 59 (1994) 71-78
161. Williams D.A., Brown S.C., Clauw D.J., and Gendreau R.M. Self-reported symptoms before and after September 11 in patients with fibromyalgia. JAMA 289 (2003) 1637-1638
162. Williams D.A., Cary M.A., Groner K.H., Chaplin W., Glazer L.J., Rodriguez A.M., and Clauw D.J. Improving physical functional status in patients with fibromyalgia: A brief cognitive behavioral intervention. J Rheumatol 29 (2002) 1280-1286
163. Willis W.D. Central plastic responses to pain. In: Gebhart G.F., Hammond D.L., and Jensen T.S. (Eds). Proceedings of the 7th World Congress on Pain. 21 Edition (1994), International Association for the Study of Pain (IASP), Seattle, WA 301-324
164. Wolfe F. The relation between tender points and fibromyalgia symptom variables: Evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56 (1997) 268-271
165. Wolfe F., Ross K., Anderson J., and Russell I.J. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 22 (1995) 151-156
166. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., and Clark P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172
167. Wood P.B., Patterson II J.C., Sunderland J.J., Tainter K.H., Glabus M.F., and Lilien D.I. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. J Pain 8 (2007) 51-58
168. Wood P.B., Schweinhardt P., Jaeger E., Dagher A., Hakyemez H., Rabiner E.A., Bushnell M.C., and Chizh B.A. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25 (2007) 3576-3582
169. Woolf C.J. Windup and central sensitization are not equivalent. Pain 66 (1996) 105-108
170. Woolf C.J. Pain: Moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140 (2004) 441-451
171. Woolf C.J., and Thompson S.W. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 44 (1991) 293-299
172. World Health Organization. International Classification of Functioning (2001), Geneva, Disability and Health
173. Xu X.J., Dalsgaard C.J., and Wiesenfeld-Hallin Z. Spinal substance P and N-methyl-D-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex. Neuroscience 51 (1992) 641-648
174. Yunus M., Masi A.T., Calabro J.J., Miller K.A., and Feigenbaum S.L. Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11 (1981) 151-171
175. Yunus M.B. Central sensitivity syndromes: A new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 37 (2008) 339-352
176. Yunus M.B., Young C.S., Saeed A.S., and Aldag J.C. Positron Emission Tomography (PET) imaging of the brain in fibromyalgia syndrome (FMS). Arthritis Rheum 40 (1997) S188
177. Yunus M.B., Dailey J.W., Aldag J.C., Masi A.T., and Jobe P.C. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 19 (1992) 90-94